IMN || Conferences

VIDEO: Don’t discount topical therapy for psoriasis

Posted on: 02/11/2014 - 15:17

LAS VEGAS– Don’t underestimate the value of topical therapy for treating psoriasis patients, Dr. Linda Stein Gold said at Skin Disease Education Foundation’s annual Las Vegas dermatology...

Field of Interest: Dermatology
Type: News Item

VIDEO: More gonadotropin, fewer live births

Posted on: 28/10/2014 - 17:59

SAN FRANCISCO– The higher the dose of gonadotropin for ovarian stimulation, the lower the live birth rate, a retrospective study of 541,967 cycles of assisted reproductive technology showed. The...

Field of Interest: Pulmonology
Type: News Item

Ovarian aging may be tip-off on cardiovascular risk

Posted on: 28/10/2014 - 15:45

HONOLULU – Women with greater ovarian reserve had lower cardiovascular risk in a prospective study of 1,092 healthy, ovulating women aged 25-45 years, 250 of whom were followed for 3-5...

Field of Interest: Pulmonology
Type: News Item

Regurgitation controlled by transoral fundoplication

Posted on: 24/10/2014 - 13:39

PHILADELPHIA – The first trial conducted in gastroesophageal reflux diseases that employed control of regurgitation as a primary endpoint found a significant advantage for transoral fundoplication...

Field of Interest: Gastroentero...
Type: News Item

Novel anticoagulants increase GI bleeds in elderly

Posted on: 23/10/2014 - 18:43

PHILADELPHIA – Dabigatran and rivaroxaban, which are rapidly replacing warfarin for anticoagulation in patients with atrial fibrillation, appear to be associated with a greater risk of GI bleeding...

Field of Interest: Gastroentero...
Type: News Item

Select biologics for dose escalation in psoriasis

Posted on: 22/10/2014 - 15:58

SONOMA, CALIF.– Data support dosage escalation or intensification for patients who don’t respond to biologic therapy for psoriasis, but only for three of the four biologic agents available in the...

Field of Interest: Dermatology
Type: News Item

Secukinumab showed sustained efficacy in psoriasis

Posted on: 19/10/2014 - 17:57

AMSTERDAM – The investigational biologic agent secukinumab continued to show strong efficacy through 52 weeks of treatment in a new secondary analysis of the pivotal phase III ERASURE trial. For...

Field of Interest: Dermatology
Type: News Item

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More
randomness